Raffaele Addeo, Carmine De Rosa, Vincenzo Faiola, Luigi Leo, Gregorio Cennamo, Liliana Montella, Rosario Guarrasi, Bruno Vincenzi, Michele Caraglia and Salvatore Del Prete Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases Cancer 113
Version of Record online: 16 SEP 2008 | DOI: 10.1002/cncr.23859
Temozolomide, an oral methylating imidazotetrazinone, has antitumor activity against gliomas, malignant melanomas, and brain metastasis and is presently administered as a 5-day oral schedule every 4 weeks.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field